Take­da takes a cau­tious step in­to neu­ro­log­i­cal gene ther­a­py, ink­ing pre­clin­i­cal deal with Stride­Bio

Sad­dled with debt and keen to di­vest non-core busi­ness amid the on­go­ing in­te­gra­tion of Shire, Take­da has nev­er­the­less dished out a small sum to beef up its neu­ro­science re­search ca­pac­i­ties, en­list­ing Durham, NC-based Stride­Bio to get start­ed on some pre­clin­i­cal gene ther­a­py can­di­dates.

At $30 mil­lion up­front and just over $700 mil­lion in to­tal deal val­ue, this doesn’t qual­i­fy as a ma­jor deal at a time many top phar­ma com­pa­nies are ag­gres­sive­ly buy­ing in­to the pop­ping gene ther­a­py space. But for Take­da — one of the biggest R&D spenders glob­al­ly — it’s a way of sig­nalling that it’s still very much ac­tive around the neu­ro­sciences deal ta­ble, seek­ing fresh as­sets to feed in­to its pipeline.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.